Iron treatment eases nausea in pregnancyEfficacy and Safety of Microsomal Ferric Pyrophosphate Supplement for Iron Deficiency Anemia in Pregnancy.
We conducted a study to examine the effectiveness of a specific iron supplement, emulsified microsomal ferric pyrophosphate (EMFP), in treating iron deficiency anemia among pregnant women. Our focus was not only on improving hemoglobin levels but also on alleviating related symptoms, including nausea.
Within 30 days of starting treatment with EMFP, we observed significant increases in hemoglobin levels, alongside marked improvements in serum ferritin and iron levels. As nausea is a common complaint among pregnant women, we noted a decrease in various symptoms, including nausea, breathlessness, and dizziness, which contributed to a better quality of life for the participants.
Notably, treatment compliance was remarkably high at 99.5%, indicating that the participants were committed to managing their anemia effectively. Importantly, we did not encounter any severe side effects related to the treatment, suggesting a favorable safety profile.
Overall, our findings support the idea that iron treatment can help alleviate nausea and other discomforts related to iron deficiency anemia in pregnancy, positively impacting both mother and baby.
Read More
FCH reduces nausea in IDA treatmentA Multicenter Single-Arm Study of Switching to Ferric Citrate Hydrate for Iron Deficiency Anemia in Patients Intolerant to Oral Iron: RIO-SWITCH.
We evaluated how switching to ferric citrate hydrate (FCH) impacts nausea in women with iron deficiency anemia (IDA) who struggled with oral iron. In a multicenter study of 30 patients, those on FCH experienced significant improvements. Nausea scores dropped from 5.7 to 1.7, and the overall incidence of nausea decreased notably. Also, 80% reported better experiences compared to previous treatments.
Overall, our findings suggest that FCH not only enhances medication adherence but also effectively reduces nausea and improves quality of life in these patients.
Read More
Vitamin D and nausea in gastroparesisLow Vitamin D Levels in Patients with Symptoms of Gastroparesis: Relationships with Nausea and Vomiting, Gastric Emptying and Gastric Myoelectrical Activity.
We delved into an intriguing question: how do low vitamin D levels affect nausea in people experiencing gastroparesis, a condition that slows gastric emptying? By measuring the vitamin D levels of patients from the Gastroparesis Clinical Consortium Registry, we aimed to uncover the relationships between vitamin D, nausea, and gastric function.
Our findings revealed that over half of the patients had low vitamin D levels, specifically 56.1% of the 513 individuals studied. We observed a clear association between these low levels of vitamin D and increased experiences of nausea and vomiting. This was particularly notable in patients with delayed gastric emptying, where those with low vitamin D levels reported significantly more nausea.
While the study showed a correlation, it did not address whether supplementing with vitamin D could directly alleviate these symptoms. Instead, we found that lower vitamin D levels also related to a greater retention of food in the stomach after meals, which hints at a connection to gastric neuromuscular dysfunction. Overall, our study emphasized a noteworthy link between vitamin D and nausea but stopped short of confirming any direct treatment benefits.
Read More
Zinc treatment reduces nausea riskRandomized, multicenter, active-controlled open-label study of NPC-25, zinc histidine hydrate, (non-inferiority to NOBELZINā¢, zinc acetate dihydrate) for patients with hypozincemia.
Asaoka D, Ishihara T, Ezoe S, Hamada I, Kitamura M, et al. Randomized, multicenter, active-controlled open-label study of NPC-25, zinc histidine hydrate, (non-inferiority to NOBELZINā¢, zinc acetate dihydrate) for patients with hypozincemia. J Trace Elem Med Biol. 2025;87:127558. doi:10.1016/j.jtemb.2024.127558 We conducted a study to evaluate how effective NPC-25, a new form of zinc, is compared to a well-known treatment, NOBELZINā¢, for patients with low zinc levels. Participants in this trial had their zinc levels checked and were grouped to receive either NPC-25 or NOBELZINā¢.
For a period of up to 24 weeks, we aimed to maintain their zinc levels within a specific target range while closely monitoring for side effects. One of our main goals was to see if NPC-25 could maintain these target zinc levels similarly to NOBELZINā¢.
Our findings revealed that NPC-25 was indeed non-inferior to NOBELZINā¢, meaning it worked just as well. Importantly, we also observed that those taking NPC-25 reported fewer digestive issues, like nausea and vomiting. This suggests that while both treatments were effective, NPC-25 might be the gentler option.
Read More
Zinc treatment in hypozincemia studyPost-marketing surveillance of zinc acetate dihydrate for hypozincemia in Japan.
We explored the impact of zinc acetate dihydrate on several symptoms, including nausea, through a comprehensive study that assessed its safety and effectiveness for treating hypozincemia over a 52-week period. From the data collected, we observed an overall adverse reaction rate of 9.4%, with nausea reported in 1.4% of patients.
Despite nausea being a concern, the benefit of zinc acetate dihydrate for other indications was notable, with an efficacy rate of 83%. For patients experiencing symptoms such as pressure ulcers or stomatitis, the effectiveness was strikingly high. However, the specific effect of zinc on nausea is not definitively isolated within the study results, making it hard to gauge its direct and unique benefits.
In essence, while zinc acetate dihydrate shows promise for a variety of symptoms, including nausea, the evidence does not conclusively highlight its effectiveness for this particular issue on its own. Overall, it appears that zinc treatment can contribute positively to addressing several related health problems.
Read More